金天格胶囊治疗绝经后骨质疏松症的药物经济学评价

Economic evaluation of Jintiange capsule in the treatment of postmenopausal osteoporosis

目的:比较金天格胶囊和仙灵骨葆胶囊治疗绝经后骨质疏松症的经济性。方法:采用多中心前瞻性观察性队列研究设计,收集自然绝经1年以上女性骨质疏松患者的相关信息,分为金天格胶囊联合双膦酸盐类治疗组(金天格组)和仙灵骨葆胶囊联合双膦酸盐类治疗组(仙灵骨葆组),并进行随访。基于中国卫生系统角度,采用倾向值匹配方法控制混杂,并对2种治疗方案进行药物经济学评价。结果:金天格组比仙灵骨葆组患者高0.016 QALYs,直接医疗成本高822元,增量成本效用比为51375元·QALY-1,低于2022年1倍中国人均GDP。结论:相较于仙灵骨葆组,金天格组用于治疗绝经后骨质疏松症更具有经济性。

Objective:To evaluate the cost-effectiveness of Jintiange Capsule and Xianlinggubao Capsule for the treatment of postmenopausal women with osteoporosis.Methods:A multicenter,prospective,observational cohort study was carried out to collect information about female patients with osteoporosis who had been naturally menopausal for more than one year.The patients were divided into two groups:the Jintiange capsule combined with bisphosphonates group(Jintiange group)and the Xianlinggubao capsule combined with bisphosphonates group(Xianlinggubao group).The patients were followed up for observation.Based on the healthcare system perspective in China,a propensity score matching method was used to control for confounders and pharmacoeconomic evaluation of the two treatment regimens was performed.Results:The Jintiange group yielded an additional 0.016 QALYs and an additional cost of 822 yuan,so the ICER was 51375 yuan·QALY~(-1),which was lower than China's per capita GDP in 2022.Conclusion:Jintiange capsule combined with bisphosphonates group is likely to be a cost-effective treatment compared with Xianlinggubao capsule plus bisphosphonates group for the treatment of postmenopausal osteoporosis.